Gilead Sciences, Inc. (LON:0QYQ)

Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of GBP 100.79 billion. The enterprise value is 113.17 billion.

Market Cap	100.79B
Enterprise Value	113.17B

Important Dates

The next estimated earnings date is Thursday, November 6, 2025.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	Sep 15, 2025

Share Statistics

Current Share Class	1.24B
Shares Outstanding	n/a
Shares Change (YoY)	+0.68%
Shares Change (QoQ)	-0.32%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.24B

Valuation Ratios

The trailing PE ratio is 21.88 and the forward PE ratio is 13.12.

PE Ratio	21.88
Forward PE	13.12
PS Ratio	4.78
PB Ratio	7.05
P/TBV Ratio	n/a
P/FCF Ratio	14.74
P/OCF Ratio	13.99
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.06, with an EV/FCF ratio of 16.55.

EV / Earnings	24.57
EV / Sales	5.35
EV / EBITDA	11.06
EV / EBIT	14.00
EV / FCF	16.55

Financial Position

The company has a current ratio of 1.32, with a Debt / Equity ratio of 1.27.

Current Ratio	1.32
Quick Ratio	0.97
Debt / Equity	1.27
Debt / EBITDA	1.79
Debt / FCF	2.66
Interest Coverage	11.04

Financial Efficiency

Return on equity (ROE) is 33.40% and return on invested capital (ROIC) is 16.02%.

Return on Equity (ROE)	33.40%
Return on Assets (ROA)	12.62%
Return on Invested Capital (ROIC)	16.02%
Return on Capital Employed (ROCE)	24.77%
Revenue Per Employee	1.20M
Profits Per Employee	261,727
Employee Count	17,600
Asset Turnover	0.53
Inventory Turnover	3.22

Taxes

In the past 12 months, Gilead Sciences has paid 649.61 million in taxes.

Income Tax	649.61M
Effective Tax Rate	12.36%

Stock Price Statistics

The stock price has increased by +40.78% in the last 52 weeks. The beta is 0.38, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.38
52-Week Price Change	+40.78%
50-Day Moving Average	114.11
200-Day Moving Average	106.08
Relative Strength Index (RSI)	39.27
Average Volume (20 Days)	23,123

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.59

Income Statement

In the last 12 months, Gilead Sciences had revenue of GBP 21.07 billion and earned 4.61 billion in profits. Earnings per share was 3.66.

Revenue	21.07B
Gross Profit	16.54B
Operating Income	8.05B
Pretax Income	5.26B
Net Income	4.61B
EBITDA	10.07B
EBIT	8.05B
Earnings Per Share (EPS)	3.66

Balance Sheet

The company has 4.42 billion in cash and 18.21 billion in debt, giving a net cash position of -12.39 billion.

Cash & Cash Equivalents	4.42B
Total Debt	18.21B
Net Cash	-12.39B
Net Cash Per Share	n/a
Equity (Book Value)	14.30B
Book Value Per Share	11.56
Working Capital	2.58B

Cash Flow

In the last 12 months, operating cash flow was 7.20 billion and capital expenditures -364.22 million, giving a free cash flow of 6.84 billion.

Operating Cash Flow	7.20B
Capital Expenditures	-364.22M
Free Cash Flow	6.84B
FCF Per Share	n/a

Margins

Gross margin is 78.53%, with operating and profit margins of 38.22% and 21.87%.

Gross Margin	78.53%
Operating Margin	38.22%
Pretax Margin	24.95%
Profit Margin	21.87%
EBITDA Margin	47.82%
EBIT Margin	38.22%
FCF Margin	32.46%

Dividends & Yields

This stock pays an annual dividend of 2.38, which amounts to a dividend yield of 2.06%.

Dividend Per Share	2.38
Dividend Yield	2.06%
Dividend Growth (YoY)	-0.02%
Years of Dividend Growth	3
Payout Ratio	62.75%
Buyback Yield	-0.68%
Shareholder Yield	1.38%
Earnings Yield	4.57%
FCF Yield	6.78%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.47 and a Piotroski F-Score of 7.

Altman Z-Score	3.47
Piotroski F-Score	7